• Thu, January 23, 2025

by: MSN

Avidity Biosciences CFO sells $93,985 in stock

Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), recently sold shares of the company stock valued at approximately $93,985. The transactions occurred on January 21,

by: Forbes

S&P 500 Index Funds: Risks You Must Know Before You Invest

Low cost S&P 500 index funds are fantastic investment vehicles but they are not without risks. We discuss these risks and how to best think about them.

by: MSN

2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025

Investing in dividend stocks with a high yield of more than 7% can significantly boost your portfolio's income potential, especially in a low-interest-rate environment. However, targeting companies with sustainable dividend payouts is crucial,

by: MSN

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.

by: MSN

Diamondback Energy's SWOT analysis: stock poised for growth amid merger synergies

Diamondback Energy Inc (NASDAQ:FANG), a leading independent oil and gas company focused on the Permian Basin with a market capitalization of $51.48 billion, has been making significant strides in operational efficiency and strategic growth.

by: MSN

Are famous short-sellers going extinct? The exit of Hindenburg Research and Andrew Left shows the risky trade is shrinking

The exposé led to the company's CEO going to jail and to Anderson's short-selling firm, Hindenburg Research, becoming one of the most feared names in corporate America. When Anderson announced last Wednesday that Hindenburg was closing shop,

by: MSN

Is AbbVie Inc. (ABBV) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other halal dividend stocks.
  • Fri, January 24, 2025

by: WOPRAI

Lisa Gill Maintained (COR) at Overweight with Increased Target to $301 on, Jan 24th, 2025

by: WOPRAI

Christopher Mcgratty Maintained (COLB) at Market with Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Patrick Scholes Maintained (CCL) at Hold with Increased Target to $30 on, Jan 24th, 2025

by: WOPRAI

Lisa Gill Maintained (CAH) at Neutral with Increased Target to $142 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (CAG) at Hold with Decreased Target to $28 on, Jan 24th, 2025

by: WOPRAI

Matthew Akers Maintained (CACI) at Overweight with Increased Target to $536 on, Jan 24th, 2025

by: WOPRAI

Joseph Greff Maintained (BYD) at Neutral with Increased Target to $80 on, Jan 24th, 2025

by: WOPRAI

Fawne Jiang Reiterated (BIDU) at Buy and Held Target at $130 on, Jan 24th, 2025

by: WOPRAI

David Williams Reiterated (BDC) at Buy and Held Target at $130 on, Jan 24th, 2025

by: WOPRAI

Jared Shaw Maintained (BANC) at Overweight with Decreased Target to $19 on, Jan 24th, 2025

by: WOPRAI

Jason Gursky Maintained (BA) at Buy with Decreased Target to $207 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (AVB) at Equal with Decreased Target to $230 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Downgraded (AVB) to Equal and Decreased Target to $223 on, Jan 24th, 2025

by: WOPRAI

Karl Shepard Maintained (ASB) at Sector with Increased Target to $27 on, Jan 24th, 2025

by: WOPRAI

David George Maintained (ASB) at Neutral with Decreased Target to $26 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (AMH) at Equal with Decreased Target to $37 on, Jan 24th, 2025

by: WOPRAI

Gregory Renza Reiterated (AMGN) at Outperform and Held Target at $324 on, Jan 24th, 2025

by: WOPRAI

David Saxon Maintained (ALC) at Buy with Decreased Target to $106 on, Jan 24th, 2025

by: WOPRAI

Brett Fishbin Maintained (ALC) at Overweight with Decreased Target to $105 on, Jan 24th, 2025

by: WOPRAI

Paul Lejuez Reinstated (ACI) to Buy and Held Target at $26 on, Jan 24th, 2025

by: WOPRAI

Wamsi Mohan Maintained (AAPL) at Buy with Decreased Target to $253 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (MAA) at Equal with Decreased Target to $152 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Upgraded (MAA) to Overweight and Increased Target to $168 on, Jan 24th, 2025

by: WOPRAI

Arvind Ramnani Maintained (MA) at Overweight with Increased Target to $591 on, Jan 24th, 2025

by: WOPRAI

Paul Lejuez Reinstated (KR) to Neutral and Held Target at $61 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (KHC) at Hold with Decreased Target to $32 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITW) at Hold with Decreased Target to $266 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITT) at Buy with Decreased Target to $179 on, Jan 24th, 2025

by: WOPRAI

Richard Newitter Maintained (ISRG) at Buy with Increased Target to $666 on, Jan 24th, 2025

by: WOPRAI

Joanne Wuensch Maintained (ISRG) at Buy with Increased Target to $711 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (IRT) at Equal with Decreased Target to $21 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (IR) at Hold with Decreased Target to $100 on, Jan 24th, 2025

by: WOPRAI

Julien Roch Upgraded (IPG) to Overweight and Increased Target to $36 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Downgraded (INVH) to Equal and Decreased Target to $35 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HSY) at Hold with Decreased Target to $170 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HAIN) at Hold with Decreased Target to $7 on, Jan 24th, 2025

by: WOPRAI

Gil Luria Maintained (GOOGL) at Neutral with Increased Target to $200 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (GIS) at Buy with Decreased Target to $72 on, Jan 24th, 2025

by: WOPRAI

Matthew Akers Maintained (GE) at Overweight with Increased Target to $250 on, Jan 24th, 2025

by: WOPRAI

Ken Herbert Maintained (GE) at Outperform with Increased Target to $220 on, Jan 24th, 2025

by: WOPRAI

Terry McEvoy Reiterated (FMBH) at Equal and Held Target at $43 on, Jan 24th, 2025

Is AbbVie Inc. (ABBV) the Best Halal Dividend Stock to Invest In Now?

We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other halal dividend stocks.
The article from MSN Money discusses whether AbbVie Inc. (ABBV) is a suitable halal dividend stock for investment. AbbVie, a pharmaceutical company, has been highlighted for its strong dividend yield and consistent dividend growth, which are attractive to investors looking for income. However, the article delves into the considerations for Muslim investors who adhere to Shariah law, which prohibits investments in companies involved in activities like alcohol, tobacco, pork, and certain financial services. AbbVie's involvement in pharmaceuticals, particularly in treatments that might not align with halal principles due to their nature or the company's financial practices, is scrutinized. The piece examines AbbVie's financial ratios to determine if it falls within the permissible limits for Shariah-compliant investments, focusing on debt levels, interest-bearing securities, and the proportion of income from non-compliant activities. It concludes that while AbbVie offers a compelling dividend profile, potential investors should carefully consider its compliance with Islamic finance principles before investing.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/top-stocks/is-abbvie-inc-abbv-the-best-halal-dividend-stock-to-invest-in-now/ar-AA1xJV8L

Like: 👍